Key Highlights

  • 0.19 USD is the projected per-share loss, per analyst consensus (EPS forecast of -0.19), for Immix Biopharma, Inc. (NASDAQ:IMMX) heading into its November 13, 2026 results, compared with 0.24 per share lost in the year-earlier period.
  • 232.1 million USD was held in cash, short-term investments and equivalents at June 30, 2026, with zero debt, and management points to funding that lasts until roughly mid-2028.
  • 12.5 million USD was the operating loss for the April to June 2026 quarter, a rise of 85% from a year before, driven by 5.33 million USD of research costs and 7.12 million USD of administrative costs.
  • 717.94 million USD reflects the Market Value shown in the screener snapshot, with the results release scheduled for after the closing bell on November 13, 2026.

What Canadian Investors Can Expect From Immix Biopharma, Inc. (NASDAQ:IMMX) on November 13, 2026

Screener data show Immix Biopharma, Inc. will publish third-quarter 2026 results after the close on November 13, 2026, with a consensus EPS of -0.19 and a valuation of USD 717.94 million. During the July to September 2025 period the company booked a loss of USD 7.59 million, or USD 0.24 per share, compared with USD 7.15 million, or USD 0.24 per share, the year before. The nine-month 2025 net loss was USD 18.75 million. Investors will weigh the new quarter against heavier spending and a much bigger number of shares following a pair of equity financings.

The Rationale: Latest Reported Quarter and Management Outlook for Immix Biopharma, Inc. (NASDAQ:IMMX)

For the quarter ended June 30, 2026, a third-party analyst note put the operating loss at USD 12.5 million, 85% above a year before and 15% above the preceding quarter. Research and Development ran to USD 5.33 million against USD 3.97 million one year earlier, while administrative overhead (general and administrative) climbed to USD 7.12 million from USD 2.75 million. Operations burned USD 11.7 million, compared with USD 9.83 million in the preceding quarter. In the NEXICART-2 trial of NXC-201, 19 of 20 evaluable patients (95%) achieved complete response, and 45 patients are planned overall. The company has signalled a BLA filing in the opening six months of 2027, with twelve-month follow-up results due March 2027.

Valuation, Liquidity and Risks for Immix Biopharma, Inc. (NASDAQ:IMMX)

Liquidity stood at USD 232.1 million on June 30, 2026, following a May 2026 offering of roughly 16.8 million shares priced at USD 8.94, which brought in about USD 150 million gross and USD 140.7 million net, along with USD 93.7 million net in December 2025. Roughly 71.5 million shares were outstanding. The analyst note quoted a market Capitalization near USD 719 million at USD 10.06 per share, whereas a different figure showed USD 620 million at USD 8.66 as of November 11, 2026, so valuation moves alongside the share price. Risks span clinical and regulatory results, Shareholder dilution, cash consumption, and the absence of product revenue.

Where Things Stand

Immix Biopharma, Inc. (NASDAQ:IMMX) heads into its report with a consensus EPS of -0.19, a valuation of USD 717.94 million in the screener snapshot along with USD 232.1 million in cash at June 30, 2026. The April to June operating loss reached USD 12.5 million, mirroring heavier outlays on research and on administration as NXC-201 advances toward a planned BLA filing in the opening six months of 2027. With no Debt and funding guided to roughly mid-2028, attention will go to outlays, study updates and schedules. Because the company earns no revenue, outcomes depend on costs, interest earned and the number of shares. This content is informational only, not a recommendation to invest.